10% owner of Clene (CLNN) reports share sales via Symbiosis II LLC

Rhea-AI Filing Summary

Clene Inc. 10% owner Ugwumba Chidozie reported indirect sales of Clene common stock through Symbiosis II, LLC. On January 22, 2026, Symbiosis II, LLC sold 12,665 shares of common stock at $5.32 per share, after which it held 605,159 shares beneficially. On January 23, 2026, it sold a further 5,556 shares at $5.27 per share, leaving 599,603 shares beneficially owned indirectly by the reporting person.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ugwumba Chidozie

(Last) (First) (Middle)

609 SW 8TH STREET

SUITE 510

(Street)

BENTONVILLE AR 72712

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Clene Inc. [ CLNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		S		12,665	D	$5.32	605,159	I	By Symbiosis II, LLC
Common Stock	01/23/2026		S		5,556	D	$5.27	599,603	I	By Symbiosis II, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Chidozie Ugwumba	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CLNN report in this Form 4?

The filing shows indirect sales of Clene Inc. common stock by a 10% owner, reported by Ugwumba Chidozie and executed through Symbiosis II, LLC.

How many Clene (CLNN) shares were sold and on which dates?

Symbiosis II, LLC sold 12,665 shares on January 22, 2026 and 5,556 shares on January 23, 2026, all reported as sales of common stock.

At what prices were the CLNN shares sold in this Form 4?

The Form 4 lists sales of Clene common stock at $5.32 per share on January 22, 2026 and $5.27 per share on January 23, 2026.

How many CLNN shares does the reporting person beneficially own after these sales?

After the January 23, 2026 transaction, 599,603 shares of Clene common stock were reported as beneficially owned, held indirectly through Symbiosis II, LLC.

Is the ownership of CLNN shares direct or indirect in this filing?

The Form 4 reports the holdings as indirect (I) ownership, with the nature of ownership described as "By Symbiosis II, LLC" for the common stock positions.

What is the relationship of the reporting person to Clene Inc. (CLNN)?

The reporting person, Ugwumba Chidozie, is identified as a 10% owner of Clene Inc. in this Form 4.